Naslov
BPC 157 therapy of portal hypertension in bile duct ligated rats

Autori
Zenko Sever, Anita ; Sever, Marko ; Drmić, Domagoj ; Romić, Željko ; Seiwerth, Sven ; Sikirić, Predrag

Vrsta, podvrsta i kategorija rada
Sažeci sa skupova, sažetak, znanstveni

Izvornik
Gastroenterology (New York, N.Y. 1943), 154 (2018), 6(S) / - , 2018, S-536

Skup
Digestive Disease Week

Mjesto i datum
Washington D.C., Sjedinjene Američke Države, 02.06.2018. - 05.06.2018

Vrsta sudjelovanja
Poster

Vrsta recenzije
Međunarodna recenzija

Ključne riječi
bile duct ligation ; portal hypertension ; BPC 157

Sažetak
Aim. We introduce the stable gastric pentadecapeptide BPC 157 in the therapy of portal hypertension in the bile duct ligated (BDL) rats. In general, after BDL in rats, BPC 157- therapy counteracted perilous patterns of microscopy (smaller intensity of architectural changes (fibrosis and cirrhosis), lower necroinflammatory score, smaller α-SMA distribution) and gross presentation (jaundice, ascites, nodular, steatotic liver, bile duct dilatation, increased liver and/or cyst weight, body weight loss, in particular) along with decreased total bilirubin, direct and indirect, ALT, AST, GGT and preserved albumin serum values. BPC 157-rats had no portal hypertension. BPC 157- therapy since week 4 improved subsequent gross, microscopy and biochemistry presentation (Gastroenterology 2014 ; 146, Issue 5, Supplement 1: S-882). Methods. In deeply anesthetized rats, blood pressure recordings were obtained over 20 min using a cannula (BD Neoflon™ Cannula) (assessed in one minute intervals) that was connected to a pressure transducer (78534C MONITOR/ TERMINAL Hewlett Packard) and was inserted in portal vein. The assessment (mmHg) was performed over the last 20 min of the 4 week-, 6 week-, 8 week-ligation-time (prophylactic regimen) or throughout the 5 min and then the following 20 min after medication at 4 week-, 6 week-, 8 week-ligation-time (delayed regimen). BPC 157 prophylactic medication. Immediately after end of anesthesia BPC 157 perorally, in drinking water (10 µg/kg, 10 ng/kg, i.e., 0.16 µg/ml, 0.16 ng/ml, 12 ml/rat/day (BPC157µg, po, BPC157ng, po) till sacrifice, or alternatively, 10 µg/kg, 10 ng/kg intraperitoneally, first application at 30 min after surgery, last at 24h before sacrifice (BPC157µg, ip, BPC157ng, ip). Delayed regimen. BPC 157 perorally, in drinking water (10 µg/kg, 0.16 µg/ml, 12 ml/rat/day) initiated at the end of the week 4 (BPC157µg PT). Immediate effect. To evaluate immediate effect on portal pressure, a local bath (5ml/kg) of saline or BPC 157 10 µg/kg, was given immediately after establishing portal hypertension values at the 4th or 6 th or 8th week. Results. Regularly present in BLD-rats, the portal hypertension did not appear in the BPC 157- rats (prophylactic medication), or it was instantly counteracted and normalized upon BPC 157 initial administration at 4, 6, or 8 week of bile duct ligation (delayed regimen ; immediate effect) (Fig.1). Conclusion. BPC 157 therapy of BLD-rats portal hypertension may be warranted for further clinical use.

Izvorni jezik
Engleski

Znanstvena područja
Temeljne medicinske znanosti

POVEZANOST RADA